Analytical Data
-
Gene name
ADRa1A
- Application
-
Alternative Names
ADR-A1A; ADRA1-A; ADRA1C; ADRA1L1; Alpha1AAR; Alpha 1a-Adrenoceptor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35348
-
Expression Region
Ser330~Val466
-
Molecular Weight
22kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ADRa1A, or alpha-1A adrenergic receptor, is a G protein-coupled receptor that plays a crucial role in various physiological processes, including smooth muscle contraction, neurotransmitter release, and cardiovascular function. Research on ADRa1A is particularly significant due to its involvement in several pathological conditions, such as hypertension, heart failure, and prostate disorders. The receptor is primarily activated by catecholamines, leading to a cascade of intracellular signaling pathways that impact vascular tone and blood pressure regulation. Understanding the structure and function of ADRa1A through recombinant protein studies has become a pivotal area of research, as it aids in elucidating the receptor's mechanisms and potential drug interactions. By employing techniques such as molecular cloning, protein expression, and purification, scientists can generate recombinant ADRa1A proteins to study their binding affinities and functional responses to various ligands. This research not only contributes to basic scientific knowledge but also opens up avenues for developing targeted therapies that can modulate ADRa1A activity, offering new treatment options for conditions related to adrenergic signaling dysregulation. Overall, the investigation of ADRa1A recombinant proteins enhances our understanding of adrenergic signaling in health and disease, underscoring its potential as a therapeutic target in pharmacology.
